About CHD1 helical C-terminal domain containing protein 1
CHD1 helical C-terminal domain containing protein 1 (CHCT1) is a protein
from Homo sapiens identified by UniProt accession
Q86WR6, 236 residues long.
MolForge cross-references it against 0 known binders and
14 disease associations.
Target properties
| Protein name | CHD1 helical C-terminal domain containing protein 1 |
|---|
| UniProt accession | Q86WR6 |
|---|
| Gene | CHCT1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 236 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (14)
Diseases linked to this target (Open Targets).
- total blood protein measurement · score 0.08
- hypoparathyroidism, familial isolated, 2 · score 0.05
- Primary hypomagnesemia with secondary hypocalcemia · score 0.05
- familial isolated hyperparathyroidism · score 0.05
- hyperparathyroidism · score 0.05
- adamantinoma · score 0.04
- Autosomal dominant primary hypomagnesemia with hypocalciuria · score 0.04
- Familial isolated hypoparathyroidism · score 0.04
- blue diaper syndrome · score 0.04
- 22q11.2 deletion syndrome · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86WR6-F1 | alphafold | PREDICTED | 68.06 | — |
Amino-acid sequence (236 residues)
MEASDGQGGE GDKPLEQVTN VSCLETSSSA SPARDSLMRH AKGLDQDTFK TCKEYLRPLK KFLRKLHLPR DLPQKKKLKY MKQSLVVLGD HINTFLQHYC QAWEIKHWRK MLWRFISLFS ELEAKQLRRL YKYTKSSQPA KFLVTFCASD APERSLLADR EDSLPKLCHA WGLHSNISGM KERLSNMQTP GQGSPLPGQP RSQDHVKKDS LRELSQKPKL KRKRIKEAPE TPETEP
Explore CHD1 helical C-terminal domain containing protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets